Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Omixon took a crack team of scary mad scientists, zombie marketeers, and bloodsucking vampires (sales people) to Denver, Colorado, to the 40th Anniversary Meeting for the American Society of Histocompatibility and Immunogenetics (ASHI). Joining the team were a couple of …more
Omixon announce today that Holotype HLA™ and other Omixon products will be featured in five posters and three oral presentations at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) held from October 20-24 in Denver, CO. …more